Business
Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":" NORTH BILLERICA, Mass.--(BUSINESS WIRE)--\nLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.\n\nThe presentation will be made available for the duration of conference.\n\nDetails for the ASCO presentation are as follows:\n\nSession Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile\nTitle: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.\nPresenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval\nAbstract No: 5023\n\nAbout Lantheus Holdings, Inc. \n\nLantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit www.lantheus.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005043/en/\n\nMark Kinarney\nSenior Director, Investor Relations\n978-671-8842\[email protected]\n\nMelis...